Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Baumann

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
Therapeutic Drug Monitoring|October 16, 2020
Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major DepressionPierre Baumann, Gilles Bertschy, Fritz Ramseier, et al.
Psychopharmacology|April 6, 2012
Flupentixol: relevance of stereoselective therapeutic drug monitoringPierre Baumann, Hartmut Kirchherr, Patricia Berney, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 5, 2002
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopramPierre Baumann, Daniele F Zullino, Chin B Eap
International Journal of Psychiatry in Clinical Practice|July 10, 2023
Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative reviewPierre Baumann, Philipp Bauknecht, Maxim Kuzin, et al.
Acta Medica (Hradec Kralove)|August 8, 2008
Off-label utilization of antidepressantsDaniele Fabio Zullino, Bruno Schwartz, Romain Bilancioni, et al.
Neuropsychobiology|January 19, 2007
Mirtazapine enantiomers in blood and cerebrospinal fluidPierre Baumann, Michèle Jonzier-Perey, Erik Paus, et al.
The International Journal of Neuropsychopharmacology|October 20, 2011
Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment responseGeorg Nikisch, Pierre Baumann, Tianmin Liu, et al.
Fundamental & Clinical Pharmacology|March 5, 2010
French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugsMichael Rougemont, Sven Ulrich, Christoph Hiemke, et al.
Journal of Clinical Psychopharmacology|November 13, 2004
High dose of depot risperidone in a nonresponder schizophrenic patientAnaïs Albrecht, Perla G Morena, Pierre Baumann, et al.
International Journal of Psychiatry in Clinical Practice|June 19, 2014
High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiencyF Haller-Gloor, Chin B Eap, Jacques Turgeon, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
Therapeutic Drug Monitoring|October 16, 2020
Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major DepressionPierre Baumann, Gilles Bertschy, Fritz Ramseier, et al.
Psychopharmacology|April 6, 2012
Flupentixol: relevance of stereoselective therapeutic drug monitoringPierre Baumann, Hartmut Kirchherr, Patricia Berney, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 5, 2002
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopramPierre Baumann, Daniele F Zullino, Chin B Eap
International Journal of Psychiatry in Clinical Practice|July 10, 2023
Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative reviewPierre Baumann, Philipp Bauknecht, Maxim Kuzin, et al.
Acta Medica (Hradec Kralove)|August 8, 2008
Off-label utilization of antidepressantsDaniele Fabio Zullino, Bruno Schwartz, Romain Bilancioni, et al.
Neuropsychobiology|January 19, 2007
Mirtazapine enantiomers in blood and cerebrospinal fluidPierre Baumann, Michèle Jonzier-Perey, Erik Paus, et al.
The International Journal of Neuropsychopharmacology|October 20, 2011
Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment responseGeorg Nikisch, Pierre Baumann, Tianmin Liu, et al.
Fundamental & Clinical Pharmacology|March 5, 2010
French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugsMichael Rougemont, Sven Ulrich, Christoph Hiemke, et al.
Journal of Clinical Psychopharmacology|November 13, 2004
High dose of depot risperidone in a nonresponder schizophrenic patientAnaïs Albrecht, Perla G Morena, Pierre Baumann, et al.
International Journal of Psychiatry in Clinical Practice|June 19, 2014
High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiencyF Haller-Gloor, Chin B Eap, Jacques Turgeon, et al.
Pageof 10